VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

Shares of VBIV stock opened at $0.61 on Thursday. The firm’s 50 day moving average price is $0.61 and its 200-day moving average price is $0.61. VBI Vaccines has a one year low of $0.45 and a one year high of $3.86. The firm has a market cap of $14.43 million, a P/E ratio of -0.05 and a beta of 1.93.

Hedge Funds Weigh In On VBI Vaccines

Large investors have recently made changes to their positions in the stock. Engineers Gate Manager LP purchased a new stake in VBI Vaccines during the 1st quarter worth approximately $26,000. Point72 Hong Kong Ltd purchased a new stake in VBI Vaccines during the 2nd quarter worth approximately $29,000. Barclays PLC increased its stake in VBI Vaccines by 89.9% during the 1st quarter. Barclays PLC now owns 98,337 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 46,566 shares during the period. Voya Investment Management LLC increased its stake in VBI Vaccines by 29.7% during the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 21,824 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in VBI Vaccines by 208.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 32,227 shares during the period. 12.26% of the stock is currently owned by institutional investors and hedge funds.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.